The purpose of this study is to study and compare the pharmacokinetics profile of low dose
raltegravir (RAL) (400mg OD and 800mg OD) and standard dose of 400mg BID in Thai HIV-infected
patients.
Phase:
Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Chulalongkorn University National Healthcare Group Pte Ltd, Singapore